Table 4.
Factors influencing disparities in chronic health conditions for childhood cancer survivors by race/ethnicity.
| Source | Risk modulators | Results of unadjusted models | Results of adjusted models | Interpretation of findings |
|---|---|---|---|---|
| NON-HISPANIC BLACK | ||||
| (27) | Pubertal status | OR = 3.11, 95% CI: 1.78–5.46 | OR = 3.25, 95% CI: 1.83–5.78 | More likelihood of vitamin-D deficiency |
| (29) | Diagnosis and fatigue | OR = 2.06, 95% CI: 0.26 = 11.85, p = 0.436 | Higher risk of obesity accounting for risk modulators. | |
| (31) | Clinical/demographic variables | RR = 0.6, 95% CI: 0.4–0.9, p = 0.009 | Higher rate of subsequent neoplasms accounting for risk modulators. | |
| (31) | Clinical/demographic variables and treatment | RR = 0.5, 95% CI: 0.3–0.8, p = 0.005 | Higher rate of subsequent neoplasms accounting for risk modulators. | |
| (31) | Clinical/demographic variables, treatment, and SES (education, income, & insurance) | RR = 0.6, 95% CI: 0.4–0.9, p = 0.01 | Higher rate of subsequent neoplasms accounting for risk modulator. | |
| (31) | Clinical/demographic variables, treatment, SES (education, income, & insurance), and CVRF (obesity, diabetes, hypertension, and dyslipidemia) | RR = 0.6, 95% CI: 0.4–0.9, p = 0.02 | Higher rate of subsequent neoplasms accounting for risk modulators. | |
| (31) | Clinical/demographic variables | RR = 1.9, 95% CI: 1.2–2.9, p = 0.005 | Higher grade cardiovascular conditions accounting for risk modulators. | |
| (31) | Clinical/demographic variables and treatment | RR = 1.8, 95% CI: 1.1–2.7, p = 0.01 | Higher grade cardiovascular conditions accounting for risk modulators. | |
| (31) | Clinical/demographic variables, treatment, and SES (education, income, & insurance) | RR = 1.6, 95% CI: 1.0–2.3, p = 0.04 | Higher grade cardiovascular conditions accounting for risk modulators. | |
| (38) | More or less that years of diagnosis | HR = 0.98, 95% CI: 0.52–1.86, p = 0.95 | HR = 1.60, 95% CI: 1.05–2.43, p = 0.03 | Higher cardiovascular after five years accounting for risk modulators. |
| (43) | Treatment, diagnosis, age and gender | RR = 0.9, 95% CI: 0.7–1.2, p = 0.32 | RR = 1.5, 95% CI: 1.0–2.1, p = 0.03 | Higher severity (Grade 3-4) in health conditions after accounting for risk modulators. |
| HISPANIC | ||||
| (27) | Pubertal status | OR = 2.08, 95% CI: 1.09–3.97 | OR = 2.14, 95% CI: 1.11–4.13 | More likelihood of vitamin-D deficiency. |
| (29) | Diagnosis and fatigue | OR= 2.29, 95% CI: 1.23–4.30 | Higher risk of obesity accounting for risk modulators. | |
| (31) | Clinical/demographic variables, treatment, SES (education, income, & insurance), and CVRF (obesity, diabetes, hypertension, and dyslipidemia) | RR= 1.6, 95% CI: 1.2–2.3, p = 0.005 | Higher rate of subsequent neoplasms accounting for risk modulators. | |
| (31) | Clinical/demographic variables, treatment, and SES (education, income, & insurance) | RR = 1.5, 95% CI: 1.1–1.2, p = 0.01 | Increased risk for endocrine conditions accounting for risk modulators. | |
| (31) | Clinical/demographic variables, treatment, SES (education, income, & insurance), and CVRF (obesity, diabetes, hypertension, and dyslipidemia) | RR = 1.6, 95% CI: 1.2–2.3, p = 0.005 | Increased risk for endocrine conditions accounting for risk modulators. | |
Bold denotes statistical significance with p < 0.05; Reference group Non-Hispanic White or Caucasian. CVRF, Cardiovascular Risk Factor; SES, Socioeconomic Status; HR, Hazards Ratio; OR, Odd Ratio; RR, Relative Ratio.